Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

A mutational significance analysis was conducted to detect novel genes and pathways in 918 patients with prostate cancer. The goal of the study was to redefine the genomic landscape of prostate cancer, says Armenia.

Twenty-three novel genes were identified that were not previously found to be significantly mutated in prostate cancer, but were recurrent in other cancers, such as 

 in breast cancer. Frequent truncating mutations in key regulators of the SWI/SNF complex such as 

 were also identified, as well as an enrichment in splicing pathway alterations in 

According to Armenia, this analysis provides a broader persepective of pathways to consider in the treatment of patients with prostate cancer.

View more from the 2017 Genitourinary Cancers Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Josh Armenia on Results of Mutated Gene Analysis in Prostate Cancer